AJ8 Stock Chart & Stats
€3.98
-€0.14(-4.14%)
At close: 4:00 PM EST
€3.98
-€0.14(-4.14%)
Day’s Range― - ―
52-Week Range€2.30 - €6.05
Previous CloseN/A
Volume0.00
Average Volume (3M)146.00
Market Cap
€126.97M
Enterprise Value€392.73M
Total Cash (Recent Filing)€35.00M
Total Debt (Recent Filing)€304.46M
Price to Earnings (P/E)2.0
Beta1.57
Next Earnings
Aug 11, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.73
Shares Outstanding41,642,430
10 Day Avg. Volume228
30 Day Avg. Volume146
Financial Highlights & Ratios
PEG Ratio9.24
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.12Price Target Upside405.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.13
Revenue Forecast (FY)€203.06M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy — BOT+BAL 3-year Phase 1b DataThree-year, fully enrolled Phase 1b durability data showing a 36-month overall survival rate of 33% and a plateau beyond two years materially de-risks the BOT+BAL program. Durable survival in a heavily pretreated MSS mCRC population supports a stronger regulatory and commercial rationale, improves the program's competitive positioning, and makes future partnerships or a pivotal program more credible to stakeholders over the coming 2–6 months and beyond.
Improving Revenue And Profitability TrendA sharp TTM swing to reported profitability alongside ~24% reported revenue growth indicates operational momentum and improved unit economics versus recent annual periods. If sustained, this trend can reduce near-term funding needs, extend runway, and provide management flexibility to prioritize pivotal trials or strategic partnerships rather than emergency financing, strengthening fundamentals over the next several quarters.
Partnership/licensing-driven Revenue ModelA business model centered on collaborations, upfront payments, milestones and royalties lets a clinical-stage biotech access non-commercial revenue and partner resources without building full commercialization infrastructure. This structure can sustainably fund development milestones, broaden program reach via partner capabilities, and lower fixed-cost burdens—advantages that persist across multiple funding cycles.
Bears Say
Persistent Negative Operating And Free Cash FlowMulti-year negative operating and free cash flow implies ongoing cash burn and dependence on external capital. That limits strategic options, increases the likelihood of dilutive financings or expensive debt, and constrains the company's ability to fund pivotal trials or expand programs organically, posing a sustained financing risk over the next several quarters.
Pressured Balance Sheet With Negative Shareholders' EquityConsistently negative stockholders' equity and relatively high debt levels weaken financial flexibility and distort leverage metrics. This pressured capital structure raises refinancing and covenant risk, reduces access to non-dilutive capital, and can force unfavorable financing terms or additional equity issuance, materially affecting stability and strategic execution over the medium term.
Dependence On Equity-linked Financing And Warrant ExtensionsRepeated extensions of maturities and issuance/extension of warrants signal reliance on equity-linked solutions to manage liquidity. While these provide near-term runway, they increase potential dilution, create share overhang, and can pressure future EPS and ownership. Dependence on such financings is a structural capital-risk that can persist until cash flows turn meaningfully positive.
Agenus News
AJ8 FAQ
What was Agenus Inc.’s price range in the past 12 months?
Agenus Inc. lowest stock price was €2.30 and its highest was €6.05 in the past 12 months.
What is Agenus Inc.’s market cap?
Agenus Inc.’s market cap is €126.97M.
When is Agenus Inc.’s upcoming earnings report date?
Agenus Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 34 days.
How were Agenus Inc.’s earnings last quarter?
Agenus Inc. released its earnings results on May 11, 2026. The company reported €0.891 earnings per share for the quarter, missing the consensus estimate of €1.835 by -€0.944.
Is Agenus Inc. overvalued?
According to Wall Street analysts Agenus Inc.’s price is currently Undervalued.
Does Agenus Inc. pay dividends?
Agenus Inc. does not currently pay dividends.
What is Agenus Inc.’s EPS estimate?
Agenus Inc.’s EPS estimate is 0.05.
How many shares outstanding does Agenus Inc. have?
Agenus Inc. has 41,642,430 shares outstanding.
What happened to Agenus Inc.’s price movement after its last earnings report?
Agenus Inc. reported an EPS of €0.891 in its last earnings report, missing expectations of €1.835. Following the earnings report the stock price went down -15%.
Which hedge fund is a major shareholder of Agenus Inc.?
Currently, no hedge funds are holding shares in DE:AJ8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€20.12 (405.61% Upside)
€20.12 (405.61% Upside)
Blogger Sentiment
Bullish
DE:AJ8 Sentiment 67%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.82%
12-Months-Change
Fundamentals
Return on Equity
-23.05%
Trailing 12-Months
Asset Growth
-6.87%
Trailing 12-Months
Company Description
Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AJ8 Stock 12 Month Forecast
Average Price Target
€20.12
▲(405.61% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Options Prices
Currently, No data available
---